Biopsy rate and nonalcoholic steatohepatitis (NASH) in patients with nonalcoholic fatty liver disease (NAFLD)

References

• Younossi ZM. Non-alcoholic fatty liver disease: a global public health perspective. J Hepatol. 2019;70(3):531–544.
   PubMed Web of Science ®Google Scholar
• Younossi ZM. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: implications for liver transplantation. Liver Transpl. 2018;24(2):166–170.
   PubMed Web of Science ®Google Scholar
• Lam B, Kurzke K, Younossi Z. The clinical and economic burden of nonalcoholic steatohepatitis. Curr Hepatology Rep. 2018;17(4):345–349.
   Google Scholar
• Estes C, Anstee QM, Arias-Loste MT, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. J Hepatol. 2018;69(4):896–904.
   PubMed Web of Science ®Google Scholar
• Hagström H, Nasr P, Ekstedt M, et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol. 2017;67(6):1265–1273.
   PubMed Web of Science ®Google Scholar
• Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149(2):389–397.e10.
   PubMed Web of Science ®Google Scholar
• Romero-Gómez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol. 2017;67(4):829–846.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Loomba R, Rinella ME, et al. Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2018;68(1):361–371.
   PubMed Web of Science ®Google Scholar
• Neuschwander-Tetri BA, Loomba R, Sanyal AJ; NASH Clinical Research Network, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015;385(9972):956–965.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Ratziu V, Loomba R; REGENERATE Study Investigators, et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2019;394(10215):2184–2196.
   PubMed Web of Science ®Google Scholar
• Do A, Llagan-Ying YC, Xu J, et al. Low eligibility for Phase 3 clinical trials in a real-life cohort with nonalcoholic steatohepatitis. Hepatology. 2018;68:184–1353.
   Google Scholar
• Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45(4):846–854.
   PubMed Web of Science ®Google Scholar
• Petta S, Wong VWS, Cammà C, et al. Serial combination of non-invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with NAFLD. Aliment Pharmacol Ther. 2017;46(6):617–627.
   PubMed Web of Science ®Google Scholar
• Kleiner DE, Brunt EM, Van Natta M; Nonalcoholic Steatohepatitis Clinical Research Network, et al. design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313–1321.
   PubMed Web of Science ®Google Scholar
• Karlas T, Petroff D, Garnov N, et al. Non-invasive assessment of hepatic steatosis in patients with NAFLD using controlled attenuation parameter and 1H-MR spectroscopy. PLoS One. 2014;9(3):e91987.
   PubMed Web of Science ®Google Scholar
• Roeb E, Steffen HM, Bantel H, et al. S2k guideline non-alcoholic fatty liver disease. Z Gastroenterol. 2015;53(7):668–723.
   PubMed Web of Science ®Google Scholar
• Karlas T, Petroff D, Sasso M, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2017;66(5):1022–1030.
   PubMed Web of Science ®Google Scholar
• Newsome PN, Sasso M, Deeks JJ, et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol. 2020;5(4):362–373.
   PubMed Web of Science ®Google Scholar
• Marchesini G, Day CP, Dufour JF, et al. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64:1388–1402.
   PubMed Web of Science ®Google Scholar
• Sberna AL, Bouillet B, Rouland A, et al. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) clinical practice recommendations for the management of non-alcoholic fatty liver disease. Diabet Med. 2018;35(3):368–375.
   PubMed Web of Science ®Google Scholar
• Blank V, Keim V, Petroff D, et al. Screening diabetic patients at risk for complications of nonalcoholic fatty liver disease: Prospective evaluation of national and international guideline recommendations. J. Hepatol. 2019;70(1):e757–8.
   Web of Science ®Google Scholar
• Labenz C, Huber Y, Kalliga E, et al. Predictors of advanced fibrosis in non-cirrhotic non-alcoholic fatty liver disease in Germany. Aliment Pharmacol Ther. 2018;48(10):1109–1116.
   PubMed Web of Science ®Google Scholar
• Hyysalo J, Männistö VT, Zhou Y, et al. A population-based study on the prevalence of NASH using scores validated against liver histology. J Hepatol. 2014;60(4):839–846.
   PubMed Web of Science ®Google Scholar
• Srivastava A, Gailer R, Tanwar S, et al. Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease. J Hepatol. 2019;71(2):371–378.
   PubMed Web of Science ®Google Scholar
• Karlas T, Petroff D, Sasso M, et al. Impact of controlled attenuation parameter on detecting fibrosis using liver stiffness measurement. Aliment Pharmacol Ther. 2018;47(7):989–1000.
   PubMed Web of Science ®Google Scholar
• Patel PJ, Banh X, Horsfall LU, et al. Underappreciation of non-alcoholic fatty liver disease by primary care clinicians: limited awareness of surrogate markers of fibrosis. Intern Med J. 2018;48(2):144–151.
   PubMed Web of Science ®Google Scholar
• Petroff D, Blüher M, Wiegand J. Knowledge and practice regarding the German and the EASL-EASD-EASO NAFLD-guidelines among members of the German Obesity Society. Dig Liver Dis. 2018;50(7):731–733.
   PubMedGoogle Scholar
• Anstee QM, Lawitz EJ, Alkhouri N, et al. Noninvasive tests accurately identify advanced fibrosis due to NASH: baseline data from the STELLAR Trials. Hepatology. 2019;70(5):1521–1530.
   PubMed Web of Science ®Google Scholar
• Boursier J, Francque S. Noninvasive tests of liver fibrosis and their combination in NAFLD: from selected patients to real-life populations. Hepatology. 2019;70(5):1500–1502.
   PubMed Web of Science ®Google Scholar
• Kramer J, Wolffram I, Früh U, et al. Laboratory reform counteracts the WHO hepatitis C elimination strategy in Germany. J. Viral Hepat. 2019;26(12):1493–1495.
   PubMed Web of Science ®Google Scholar